Which antidiabetic medications are contraindicated in type 2 diabetes mellitus?

Antidiabetic Medications Contraindicated in Type 2 Diabetes Mellitus

The primary absolute contraindications in T2DM are: thiazolidinediones (pioglitazone, rosiglitazone) in patients with heart failure, saxagliptin in patients with high HF risk, metformin when eGFR <30 mL/min/1.73 m², and aliskiren in heart failure with reduced ejection fraction.

Specific Contraindications by Drug Class

Thiazolidinediones (TZDs)

• Absolutely contraindicated in heart failure 1
• Both pioglitazone and rosiglitazone are not recommended in patients with HF due to fluid retention and worsening of heart failure symptoms
• This applies to both NYHA class III and IV heart failure 2

DPP-4 Inhibitors

• Saxagliptin is specifically not recommended in patients with T2DM and high risk of heart failure 1
• Other DPP-4 inhibitors (sitagliptin, linagliptin) have neutral effects on HF and may be used 1

Metformin

Critical eGFR-based contraindications 3:

• Absolute contraindication: eGFR <30 mL/min/1.73 m² - stop metformin immediately; do not initiate
• Must be discontinued before initiating dialysis
• Requires dose adjustment when eGFR 30-44 mL/min/1.73 m² (halve the dose)
• Consider dose reduction when eGFR 45-59 mL/min/1.73 m² in certain conditions

Additional metformin contraindications:

• Acute myocardial infarction (though only 17.5% discontinue in practice) 4
• Severe hepatic impairment/chronic liver disease 4
• Conditions predisposing to lactic acidosis
• Should be withheld if renal function deteriorates after angiography 1

Renin-Angiotensin System Agents

• Aliskiren (direct renin inhibitor) is not recommended in heart failure with reduced ejection fraction and diabetes 1

Context-Specific Contraindications

Pregnancy and Reproductive Health

• Statins are not recommended in women of childbearing potential 1
• While not antidiabetics per se, this is relevant for comprehensive T2DM management

GLP-1 Receptor Agonists

• Contraindicated in patients with:
  • Active multiple endocrine neoplasia type 2 (MEN2)
  • Personal or family history of medullary thyroid carcinoma 2

Important Clinical Caveats

Combination Therapy Restrictions

• Do not combine DPP-4 inhibitors with GLP-1 RAs or dual GIP/GLP-1 RAs - no additional glucose lowering benefit and unnecessary treatment burden 5

Monitoring Requirements

The KDIGO 2022 guidelines emphasize that metformin requires vigilant monitoring 3:

• Monitor eGFR at least annually when eGFR ≥60
• Increase monitoring frequency to every 3-6 months when eGFR <60
• Monitor vitamin B12 after 4 years of continuous use

Real-World Practice Gap

Despite clear contraindications, adherence to prescribing guidelines is poor. A population study found that 24.5% of patients prescribed metformin had contraindications to its use, yet development of contraindications rarely resulted in discontinuation 4. This underscores the need for systematic monitoring and medication review.

Algorithmic Approach to Avoiding Contraindications

Before prescribing any antidiabetic:

1. Check eGFR - determines metformin eligibility and dosing
2. Assess heart failure status - excludes TZDs and saxagliptin if HF present or high risk
3. Review cardiac history - recent MI may warrant metformin caution
4. Screen for thyroid cancer history - excludes GLP-1 RAs if MEN2 or medullary thyroid carcinoma
5. Evaluate liver function - severe hepatic disease contraindicates metformin
6. Check current medications - avoid DPP-4i + GLP-1 RA combinations

The evidence strongly supports that SGLT2 inhibitors have no absolute contraindications in T2DM and are actually recommended as first-line therapy alongside metformin when eGFR ≥30 3, making them the safest class from a contraindication standpoint.